Why India rejected a patent application for shorter drug-resistant TB treatment | Explained

This case highlights the crucial balance in India's Intellectual Property Rights (IPR) regime, specifically regarding pharmaceutical patents. Section 3(d) of the Indian Patents Act, 1970 is the key framework here; it prevents 'evergreening'—the practice of seeking patents for minor modifications of existing drugs without significantly enhancing their efficacy. The rejection of the BPaL patent suggests the Indian Patent Office viewed the combination of existing drugs (bedaquiline and linezolid are already known) as lacking the necessary inventive step or enhanced efficacy required under Indian law to warrant a new patent. This provision is central to India's strategy of ensuring access to affordable medicines while complying with the TRIPS Agreement.

The public health implications of this decision are profound, particularly for India, which bears the highest global burden of tuberculosis. Drug-Resistant TB (DR-TB) is traditionally difficult to treat, requiring lengthy regimens (up to 24 months) with severe side effects and high costs, leading to poor adherence. The World Health Organization recommends the shorter, all-oral BPaL regimen because it drastically reduces treatment time and improves patient compliance. By rejecting the patent, India ensures that generic drug makers can produce affordable versions of BPaL, significantly lowering the cost of this life-saving treatment and accelerating progress towards the National Strategic Plan for Tuberculosis Elimination.

The rejection underscores India's role as the 'pharmacy of the developing world.' The ability of Indian generic manufacturers to produce affordable DR-TB drugs will not only benefit Indian patients but also patients in low- and middle-income countries globally. A patent grant would have established a monopoly for the patent holder, keeping prices high and restricting market access. This decision supports the domestic pharmaceutical industry's growth by opening the market for generic competition, ultimately driving down costs and improving the economic viability of national health programs targeting tuberculosis.